Caprelsa is a kinase inhibitor used to treat symptomatic or progressive medullary thyroid cancer (MTC) in patients with unresectable locally advanced or metastatic disease.

Recommended Dosage: The recommended dose is 300 mg taken orally once daily until disease is progressive or unacceptable toxicity occurs. Caprelsa tablets may be taken with or without food. Do not take a missed dose within 12 hours of the next scheduled dose. Do not crush the tablets of Caprelsa. 

Tablets can be dispersed in 2 ounces of water by stirring for around 10 minutes (will not completely dissolve). Do not use any kind of other liquids for dispersion. Swallow promptly after dispersion. Mix any remaining residue with four additional ounces of water and swallow. The dispersion may also be given with the help of nasogastric or gastrostomy tubes

• Obtain an ECG and serum potassium, magnesium, calcium and TSH at baseline, 2-4 weeks and 8-12 weeks after starting treatment with caprelsa 300 mg, and every 3 months thereafter. Monitor ECGs and electrolytes more frequently in patients who experience diarrhea. 
• Avoid using Vandetanib with medicines known to prolong the QT interval. If such medications are given to patients already taking Vandetanib and no alternative therapy exists, perform ECG monitoring of the QT interval more frequently.
• Severe skin reactions (including Stevens-Johnson syndrome), some leading to death, have noted in patients treated with vandetanib 300 mg tablets. Consider permanent interruption of vandetanib for severe skin reactions. Photosensitivity reactions can occur during therapy and up to 4 months after the interruption of therapy. 
• Interstitial Lung Disease (ILD) or pneumonitis, including fatalities, has observed in patients treated with this kinase inhibitor. Consider a diagnosis of ILD in patients presenting with non-specific respiratory signs/symptoms. Interrupt caprelsa 300 mg tablets, for acute or worsening pulmonary symptoms. Discontinue treatment if ILD is confirmed.
• Ischemic cerebrovascular events, including fatalities, emerged in patients treated with the tablets of Caprelsa. Discontinue treatment with Caprelsa in those patients who experience a severe ischemic cerebrovascular event.
• Heart failure, including fatalities, observed in patients treated with Vandetanib. Monitor for signs/symptoms of heart failure. Consider interription of therapy in patients with heart failure. Heart failure may not be reversible upon stopping the therapy.
• Severe hemorrhagic events, including fatalities, emerged in patients treated with caprelsa tablets 300 mg. Do not administer the medication to patients with a recent history of hemoptysis of ≥1/2 teaspoon of red blood. Discontinue therapy in patients with severe hemorrhage.
• Obtain Thyroid-stimulating hormone (TSH) at baseline, at 2 to 4 weeks and 8 to 12 weeks after starting treatment with Vandetanib, and every 3 months thereafter. In case signs/symptoms of hypothyroidism appear, assess thyroid hormone levels and adjust thyroid replacement therapy accordingly.
• Hypertension, including hypertensive crisis, may occur in patients treated with tab caprelsa 300 mg. Evaluate all patients for hypertension. Dose interruption or reduction for hypertension may be required. In case hypertension cannot be controlled, do not resume treatment. 
• On behalf of its mechanism of action, Vandetanib can cause fetal harm if used by a pregnant woman. If Vandetanib is used during pregnancy, or if the patient becomes pregnant while taking it, the patient needs to be apprised of the potential hazard to a fetus. Women of childbearing age should avoid pregna

What documents are required to import CAPRELSA to India?

CAPRELSA (vandetanib) tablets can be imported by patients or government hospitals on the name of the patients only. 

The following documentation required to import the product:

• Valid prescription from a qualified doctor.
• Patients diagnostic reports
• Patients id proof (issued by government of India)

How does order be confirmed?

The order will be confirmed only after the receipt of:

• Valid prescription of Doctor
• Import permit if applicable

Is CAPRELSA available in India?

CAPRELSA (vandetanib tablets) is a (prescription drug, prescription medication or prescription medicine) pharmaceutical drug that legally requires a medical prescription to be dispensed.

IPN (Indian Pharma Network) helps import cancer medicines on the named patient supply (NPS). Indian Pharma Network is facilitator providing input

• On availability in India (Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore and Pune etc.)
• Medicine Price.
• Finding Genuine and reliable source from Canada, Europe, USA and Australia
• Ensuring 100% transparency.

CAPRELSA can be made available to patients, doctors and hospitals at Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow and Pune and other cities in India. The order will be confirmed only after the receipt of a valid prescription from the doctor and import permit.

IPN (Indian Pharma Network) can facilitate the supply of CAPRELSA (prescription medicines) to all locations in the world and in India after fulfilling the legal requirement (if applicable)

Please contact +91-9310090915 | Toll-Free No: 1800-889-1064 or write us at info@indianpharmanetwork.in for Caprelsa tablet price in India. 

We take guarantee of quality and delivery anywhere in the world as per the buyer’s requirements.

Indian Pharma Network is able to source CAPRELSA (Cancer Treatment Medicines) from across the globe, and has the ability to supply. Indian Pharma offers its customers worldwide access to the best available treatment.

Indian Pharma Network is able to dispense any valid prescription in the shortest possible time. All prescriptions are dispensed and checked by registered pharmacists and dispatched to the Patient’s address only from New Delhi, India.

What is the Generic Name for the trade name drug Caprelsa®?

Vandetanib is Generic Name for the trade name drug Caprelsa®.

Is Caprelsa® approved by the FDA?

Yes, Caprelsa® is approved by the FDA. Date of approval: April 6, 2011.

Who should not take Caprelsa® Tablets? 

Do not take caprelsa tablets in case you have had QT prolongation.

What are the most common side effects due to Caprelsa®? 

Most common side effects due to Caprelsa® include: rash, diarrhea, acne, nausea, high blood pressure, headache, loss of appetite, feeling tired, upper respiratory tract infections and stomach (abdominal) pain. 

How much does Caprelsa® cost in India?

The caprelsa cost in India is less and reasonable. In order to procure this thyroid cancer medication authentically, you can call or WhatsApp +91-9310090915 or send mail to info@indianpharmanetwork.in.

What are the storage conditions of Caprelsa®?

Caprelsa should be stored at 25°C (77°F); excursions permitted to 15°C to 30°C (59°F to 86°F). Procedures for proper handling and disposal of anticancer medications should be considered. Do not crush the pills of Caprelsa.

Is it safe to buy Caprelsa® online in India? 

Yes, You can buy Caprelsa online in India from https://www.indianpharmanetwork.in/ if the drug has not been approved or is not available in your country.

What are the Highlights of prescribing information for Caprelsa®?

Click Here to download full Caprelsa prescribing information.